



AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

February 19, 2020

Cambridge, MA, February 19, 2020 – AlloVir, a late-clinical stage T-cell immunotherapy company, today announced that its Chief Executive Officer, David Hallal will present at the 9th annual SVB Leerink Global Healthcare Conference on Tuesday February 25th at 2:00 PM ET at the Lotte New York Palace in New York City. AlloVir, an ElevateBio portfolio company, is the leader in the development of novel cell therapies with a focus on restoring and maintaining virus-specific T-cell immunity in patients suffering from, or at risk for, life-threatening viral diseases.

About Viralym-M (ALVR105)

Viralym-M is the lead investigational therapy in AlloVir's pipeline of allogeneic, off-the shelf multi-virus specific T-cell therapies designed to treat active viral diseases in immunocompromised patients, including in patients following HSCT, solid organ transplant, or in patients suffering with primary immunodeficiencies, cancer, or HIV. In a positive Phase 2 proof-of-concept study, published in the *Journal of Clinical Oncology* (Tzannou, JCO, 2017), greater than 90% of patients who failed conventional treatment and received Viralym-M demonstrated a complete or partial clinical response, and most exhibited complete resolution of major clinical symptoms. Viralym-M has the potential to fight or prevent a range of severe and life-threatening viral diseases in patients while they are immunocompromised.

About AlloVir

AlloVir (formerly ViraCyte), founded in 2013 by researchers at Baylor College of Medicine's Center for Cell and Gene Therapy, is the leader in the development of novel cell therapies with a focus on restoring and maintaining virus-specific T-cell immunity in patients suffering from, or at risk for, life-threatening viral diseases. The company's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for patients under viral attack. AlloVir's technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with its lead allogeneic product, Viralym-M (ALVR105), and allows potentially hundreds of patients to be treated with virus-specific T-cells manufactured from a single donor, using a proprietary cell selection strategy to match the company's bank of donor-derived cell lines to patients. AlloVir is advancing multiple mid- and late-stage clinical trials across its product portfolio.

AlloVir is an ElevateBio portfolio company. More information can be found at allovir.com.

Media contact:

Courtney Heath
ScientPR
AlloVirPR@scientpr.com
617-872-2462